CAMBRIDGE, Mass., May 2, 2019 /PRNewswire/ -- Blueprint
Medicines Corporation (NASDAQ: BPMC), a precision therapy company
focused on genomically defined cancers, rare diseases and cancer
immunotherapy, today announced that it will host a live conference
call and webcast at 8:30 a.m. ET on
Thursday, May 9, 2019 to report its first quarter 2019
financial results and provide a corporate update.
To access the live conference call, please dial (855) 728-4793
(domestic) or (503) 343-6666 (international), and refer to
conference ID 9671728. A webcast of the call will also be available
under "Events and Presentations" in the Investors & Media
section of the Blueprint Medicines website at
http://ir.blueprintmedicines.com/. The archived webcast will be
available on Blueprint Medicines' website approximately two hours
after the conference call and will be available for 30 days
following the call.
About Blueprint Medicines
Blueprint Medicines is a precision therapy company striving
to improve human health. With a focus on genomically defined
cancers, rare diseases and cancer immunotherapy, we are developing
transformational medicines rooted in our leading expertise in
protein kinases, which are proven drivers of disease. Our uniquely
targeted, scalable approach empowers the rapid design and
development of new treatments and increases the likelihood of
clinical success. We are currently advancing four investigational
medicines in clinical development, along with multiple research
programs. For more information,
visit www.BlueprintMedicines.com and follow us
on Twitter (@BlueprintMeds) and LinkedIn.
View original content to download
multimedia:http://www.prnewswire.com/news-releases/blueprint-medicines-to-report-first-quarter-2019-financial-results-on-thursday-may-9-2019-300842326.html
SOURCE Blueprint Medicines